No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at the Institute for Clinical and Economic Review (ICER). But ...
Vertex aims to file its application for approval of VX-770 with the European Medicines Agency by the end of this month. The EMA has already granted the company an expedited review for the drug to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results